Compare CRC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | VKTX |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.0B |
| IPO Year | 2020 | 2014 |
| Metric | CRC | VKTX |
|---|---|---|
| Price | $56.74 | $31.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $72.57 | ★ $95.86 |
| AVG Volume (30 Days) | 710.0K | ★ 1.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,669,000,000.00 | N/A |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.73 | N/A |
| 52 Week Low | $43.25 | $22.96 |
| 52 Week High | $71.98 | $43.15 |
| Indicator | CRC | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 42.69 |
| Support Level | $50.42 | $31.58 |
| Resistance Level | $63.65 | $32.92 |
| Average True Range (ATR) | 1.37 | 1.37 |
| MACD | 0.39 | -0.05 |
| Stochastic Oscillator | 74.16 | 17.91 |
California Resources Corp is an independent oil and natural gas exploration and production company. The company has operations spread across different properties in several oil and gas exploration basins in California and Utah, such as the Midway-Sunset, South Belridge, and McKittrick fields, in the San Joaquin Basin, and other properties located in Los Angeles, Sacramento, Uinta, and the Ventura and Salinas basins. Additionally, the company is focused on maximizing the value of its land, mineral ownership, and energy expertise for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects. Its business is organized into two reporting segments: oil and natural gas, which generate maximum revenue, and carbon management.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.